5174 Predictive factors of response to neoadjuvant 3-weekly epirubicin (EPI) plus docetaxel (DOC) chemotherapy (CT) in locally advanced breast cancer (LABC): a prospective phase II trial

✍ Scribed by Strada, M.R.; Frascaroli, M.; Palumbo, R.; Bernardo, A.; Villani, L.; Scelsi, M.; Jedrychowska, I.; Albanese, D.; Teragni, C.; Bernardo, G.

• Book ID: 122705617
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 46 KB
• Volume: 7
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/S1359-6349(09)71066-3